Ascendis Pharma A Quick Ratio (ASND) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Ascendis Pharma A  (NASDAQ: ASND)

Ascendis Pharma A's Quick Ratio

ASND's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.58 a new company low.

Within Major Pharmaceutical Preparations industry 415 other companies have achieved higher Quick Ratio than Ascendis Pharma A in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 2440.

Explain Quick Ratio?
How much Cash & cash equivalents ASND´s has?
What are ASND´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ASND Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 17.79 % 17.79 % 17.79 % 17.79 % 24.8 %
Y / Y Cash & cash equivalent Change 10.07 % -1.02 % 10.07 % 10.07 % 44.62 %
Quick Ratio MRQ 0.58 0.58 0.58 0.58 0.62
ASND's Total Ranking # 2440 # 0 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % 17.79 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % 10.07 % -10.08 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 416
Healthcare Sector # 768
Overall Market # 2440


Quick Ratio Statistics
High Average Low
12.49 4.46 0.58
(Dec 31 2019)   (Dec 31 2025)




Financial Statements
Ascendis Pharma A's Current Liabilities $ 1,198 Millions Visit ASND's Balance sheet
Ascendis Pharma A's Cash & cash equivalent $ 692 Millions Visit ASND's Balance sheet
Source of ASND's Sales Visit ASND's Sales by Geography


Cumulative Ascendis Pharma A's Quick Ratio

ASND's Quick Ratio for the trailling 12 Months

ASND Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 17.79 % 19.27 % 28.05 % 42.39 % 62.3 %
Y / Y Cash & cash equivalent TTM Growth 7.07 % 13.11 % 25.49 % 34.84 % 37.39 %
Quick Ratio TTM 0.58 0.59 0.61 0.62 0.64
Total Ranking TTM # 4004 # 0 # # #
Seq. Current Liabilities TTM Growth 3.92 % 4.08 % 4.26 % 4.45 % 5.23 %
Seq. Cash & cash equivalent TTM Growth 2.34 % -0.26 % 2.39 % 2.45 % 8.11 %

Quick ratio ranking by company, industry and sector >> Back to ASND Financial Strength Comparisons >> Go to Compare ASND Quick Ratio to its Competitors

  News about Ascendis Pharma A Quick Ratio

Ascendis Pharma Secures $150 Million Royalty Funding Agreement with Royalty Pharma to Drive Innovation in Endocrine Rare Disease Therapies,


Ascendis Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative therapies for rare endocrine diseases, has announced a significant financial milestone. The company has entered into a $150 million royalty funding agreement with Royalty Pharma, a renowned investor in healthcare royalties. This funding will be used to support the continued development and commercialization of Ascendis Pharmans endocrine rare disease products, including the highly anticipated U.S. commercial launch of YORVIPATH, as well as for general corporate purposes.
The agreement with Royalty Pharma comes at a crucial time for Ascendis Pharma as the company seeks to expand its reach and bring groundbreaking therapies to patients suffering from rare endocrine diseases. The funds will provide the necessary capital to advance ongoing clinical trials, conduct research and development activities, and support the commercialization efforts of YORVIPATH and other promising therapies in Ascendis Pharmans pipeline.

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $1,197.72 millions, cumulative Quick Ratio decreased to 0.58 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 483 other companies have achieved higher Quick Ratio than Ascendis Pharma A. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 4004.

Explain Quick Ratio?
How much Cash & cash equivalents ASND´s has?
What are ASND´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 484
Healthcare Sector # 992
Within the Market # 4004


trailing twelve months Quick Ratio Statistics
High Average Low
12.49 5.06 0.58
(Dec 31 2019)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Werewolf Therapeutics Inc   1.58 $ 57.050  Millions$ 36.148  Millions
Therapeuticsmd Inc   1.56 $ 7.483  Millions$ 4.785  Millions
Rigel Pharmaceuticals Inc  1.56 $ 154.955  Millions$ 99.237  Millions
Emergent Biosolutions Inc   1.55 $ 205.400  Millions$ 132.200  Millions
60 Degrees Pharmaceuticals Inc   1.49 $ 2.751  Millions$ 1.843  Millions
Maia Biotechnology Inc   1.48 $ 8.658  Millions$ 5.836  Millions
Apellis Pharmaceuticals Inc   1.47 $ 466.233  Millions$ 316.509  Millions
Sarepta Therapeutics Inc   1.43 $ 939.650  Millions$ 656.648  Millions
Legend Biotech Corporation  1.42 $ 901.900  Millions$ 636.400  Millions
Ibio inc   1.41 $ 8.608  Millions$ 6.106  Millions
Indaptus Therapeutics Inc   1.38 $ 8.508  Millions$ 6.159  Millions
Macrogenics Inc   1.38 $ 57.217  Millions$ 41.586  Millions
Arcutis Biotherapeutics Inc   1.37 $ 178.075  Millions$ 129.838  Millions
Addex Therapeutics Ltd  1.37 $ 1.639  Millions$ 1.199  Millions
Inflarx N V  1.34 $ 19.545  Millions$ 14.540  Millions
Inovio Pharmaceuticals Inc   1.34 $ 58.512  Millions$ 43.669  Millions
Inventiva S a   1.31 $ 113.784  Millions$ 86.663  Millions
Theriva Biologics inc   1.30 $ 13.056  Millions$ 10.014  Millions
Moleculin Biotech Inc   1.30 $ 8.878  Millions$ 6.854  Millions
Uniqure N v   1.28 $ 80.240  Millions$ 62.919  Millions
Apimeds Pharmaceuticals US, Inc.  1.26 $ 13.273  Millions$ 10.545  Millions
Vireo Growth Inc.  1.25 $ 103.230  Millions$ 82.545  Millions
Vanda Pharmaceuticals Inc   1.24 $ 84.851  Millions$ 68.297  Millions
Amicus Therapeutics inc   1.23 $ 293.536  Millions$ 237.828  Millions
Nkarta Inc   1.23 $ 39.634  Millions$ 32.122  Millions
Immunoprecise Antibodies Ltd   1.21 $ 7.919  Millions$ 6.527  Millions
Puma Biotechnology Inc   1.20 $ 97.528  Millions$ 81.253  Millions
Greenwich Lifesciences Inc   1.20 $ 6.178  Millions$ 5.151  Millions
Nature s Sunshine Products inc   1.20 $ 93.891  Millions$ 78.538  Millions
Nanoviricides inc   1.19 $ 1.559  Millions$ 1.307  Millions

Date modified: 2026-09-18T14:10:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.